抑制CYP1A1可以减轻素诱导的肝毒性
Ruoyue Huang1, Jingyi Duan1, Wen Huang2
1Department of Gastroenterology & Hepatology, Laboratory of Metabolomics and Drug-Induced Liver Injury, State Key Laboratory of Biotherapy, and Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu 610041, China.
Toxins
|January 22, 2024
概括
过量服用胆固醇可以导致肝损伤. 抑制CYP1A1通过CASPASE-1-GSDMD途径减少氧化应激和热,从而减轻这种损伤,这表明CYP1A1是治疗点.
科学领域:
- 药理学 药理学是指药理学的学科.
- 肝毒性 肝毒性 肝毒性
- 分子生物学分子生物学
背景情况:
- 来自Colchicum autumnale的科尔奇辛具有治疗用途,但在过量服用后可能导致致命的肝损伤的风险.
- 了解素诱导的肝毒性机制对于安全的临床应用至关重要.
- 细胞染色体P450 1A1 (CYP1A1) 已涉及到菌素的毒性和代谢.
研究的目的:
- 为了阐明CYP1A1在素诱导的肝损伤中的作用.
- 调查向CYP1A1的潜力,以减轻菌素的肝毒性.
主要方法:
- 研究了CYP1A1在菌素肝毒性中的参与.
- 评估CYP1A1抑制对肝脏组织中氧化应激和热的影响.
- 在小鼠模型中研究了CASPASE-1-GSDMD通路的调节,该模型对素诱导的肝损伤进行了研究.
主要成果:
- CYP1A1在菌素诱导的肝毒性中起着重要作用,并且可能参与其代谢.
- 抑制CYP1A1降低了经过胆固醇治疗后肝脏中氧化应激和热的发生.
- 通过CASPASE-1-GSDMD途径调节CYP1A1活性,有效地改善了小鼠模型中的肝损伤.
结论:
- CYP1A1是胆固醇诱导的肝损伤的关键媒介.
- 抑制CYP1A1提供了一种潜在的治疗策略,以减轻菌素的肝毒性.
- 通过CASPASE-1-GSDMD途径向CYP1A1可能会保护肝脏免受过量服用胆固醇的损伤.
更多相关视频
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
142
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
142
Hepatic Drug Excretion: Enterohepatic Cycling
1.5K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
1.5K
Combined Effects of Drugs: Synergism
3.9K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
3.9K
Enhanced Elimination of Poison
514
Poison can be effectively removed from the gastrointestinal (GI) tract through various decontamination procedures.
Antidotes serve a crucial role in counteracting the effects of poison by inhibiting enzymes responsible for producing harmful drug metabolites. In some cases, these toxic metabolites can be neutralized by endogenous cosubstrates, which are maintained at specific concentrations to prevent interaction with cellular macromolecules and subsequent cell death.
Renal excretion is the...
Antidotes serve a crucial role in counteracting the effects of poison by inhibiting enzymes responsible for producing harmful drug metabolites. In some cases, these toxic metabolites can be neutralized by endogenous cosubstrates, which are maintained at specific concentrations to prevent interaction with cellular macromolecules and subsequent cell death.
Renal excretion is the...
514
Allosteric Proteins-ATCase
5.7K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.7K
Factors Influencing Drug Absorption: Disease States and Pharmacology
519
Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
519


